Scynexis Implements 1-for-8 Reverse Stock Split to Meet Nasdaq Listing Requirements
Event summary
- Scynexis will execute a 1-for-8 reverse stock split effective May 29, 2026, reducing outstanding shares from ~79.5 million to ~9.9 million.
- The split was approved by stockholders on May 19, 2026, and is intended to comply with Nasdaq's minimum bid price requirement.
- Trading on a split-adjusted basis begins June 1, 2026, under the same ticker (SCYX) but with a new CUSIP number.
- No fractional shares will be issued; affected shareholders will receive cash payments instead.
- The company's authorized shares will decrease from 150 million to 18.75 million, with no change in par value per share.
The big picture
Scynexis's reverse stock split is a defensive move to maintain Nasdaq listing eligibility, a common tactic for clinical-stage biotechs facing share price pressures. The company's focus on rare disease treatments and antifungal innovations positions it in a niche but competitive space, where regulatory approvals and partnership deals (like its GSK collaboration) will be critical for long-term viability. The split's success hinges on whether it stabilizes the stock price without alienating retail investors or triggering further governance scrutiny.
What we're watching
- Liquidity Impact
- How the reduced share count will affect trading liquidity and institutional investor participation.
- Market Perception
- Whether the reverse split will be interpreted as a sign of financial distress or a strategic necessity.
- Clinical Milestones
- The pace at which Scynexis advances its SCY-770 Phase 2 study and SCY-247 Phase 1 IV trial, given the extended cash runway to mid-2029.
Related topics